Max Healthcare Q1 FY27: ₹425 cr capex, ₹323 cr profit

Board meeting: results, capex, and leadership updates

Max Healthcare Institute Limited said its Board of Directors met on August 13, 2026, to take up a set of operational and financial decisions. The company approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). It also cleared a large capital expenditure plan for the expansion of its Max Super Speciality Hospital in Vaishali. Alongside, the board approved changes in Senior Management Personnel, including two appointments and one resignation. The company also received in-principle approval to explore medical colleges and medical institutions under an evolving regulatory backdrop. The meeting began at 11:48 AM IST and concluded at 2:19 PM IST. The company said the disclosure will be hosted on its website at www.maxhealthcare.in.

Q1 FY27 financial results approved (unaudited)

The board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. On a consolidated basis, Max Healthcare reported profit for the period of ₹322.96 crore. On a standalone basis, profit for the period was ₹167.60 crore. Consolidated revenue from operations for the quarter stood at ₹2,366.17 crore. Standalone revenue from operations was ₹782.92 crore. The company’s disclosure describes these as unaudited numbers for the quarter. The approval came as part of the scheduled board meeting agenda for quarterly results.

Vaishali hospital expansion: ₹425 crore capex, ~250 beds

A key decision at the meeting was the approval of capital expenditure of approximately ₹425 crore. The capex is for the expansion of the Max Super Speciality Hospital in Vaishali. The company said this expansion is expected to add around 250 beds. The announcement positions the investment as part of the company’s broader effort to expand healthcare infrastructure to meet growing demand. No project timeline, phased commissioning schedule, or funding mix was specified in the provided disclosure. The decision still stands out as a material capacity addition for a single facility.

Senior management changes: two appointments, one resignation

The board approved changes within its Senior Management Personnel. Mr. Ajay Vij has been appointed as Director – Chief Supply Chain & Procurement Officer, effective August 14, 2026. Mr. Pawan Kumar Marella has been appointed as Senior Director – Chief Experience & Brand Officer, effective August 17, 2026. Separately, Dr. N. Venkatesan, Senior Director and Chief Procurement Officer, has resigned. The company said he will cease to be a Senior Management Personnel effective August 31, 2026, to pursue future career opportunities. The disclosure does not mention any interim arrangement for the procurement leadership transition.

Medical colleges plan: in-principle approval linked to NMC proposals

The board gave in-principle approval to explore and evaluate the establishment of medical colleges and medical institutions. The company said this could be done either directly or through subsidiaries. This step was linked to proposed amendments by the National Medical Commission (NMC) that would allow companies incorporated under the Companies Act, 2013, to pursue such activities. Concurrently, the company said its Memorandum of Association will be amended to incorporate additional enabling objects aligned with its long-term business strategy. The update indicates preparatory work rather than a confirmed launch or specific investment commitment. No campus location, capacity, or timeline was disclosed.

Trading window and investor communication

Ahead of the results, the company indicated that the trading window for its securities (Symbol: MAXHEALTH, Scrip Code: 543220) remained closed for all designated persons and their immediate relatives. It said the closure would continue until 48 hours after the declaration of the financial results. The board meeting to consider Q1 FY27 results was scheduled for August 13, 2026, in the company’s board meeting notice. Max Healthcare also planned an earnings call for investors and analysts to discuss the financial results for the quarter ended June 30, 2026. The concall was scheduled for Friday, August 14, 2026 at 11:00 AM IST.

Stock and valuation snapshots cited in the disclosure stream

Market data points referenced alongside the corporate update showed MAXHEALTH trading around the ₹1,007 to ₹1,013 range on August 13, 2026. One data point cited MAXHEALTH stock price at ₹1,013.3 as of 13 Aug, 2026, while another cited a live price of ₹1,007.50. The stock was also cited at ₹1,007.5 on NSE and ₹1,008 on BSE as on 12/8/2026, with an open of ₹1,030.8 and a previous close of ₹1,040 in the same data flow. The Price-to-earnings (P/E) ratio was cited at 68.02, and the price-to-book (PB) ratio at 9.1 (as on 12 August, 2026 | 11:18). Market capitalisation was cited at ₹98,057.3 crore (as on 12 August, 2026 | 11:18). Separately, a market note stated the shares slipped by 0.22% on Friday, settling at ₹1,070, without specifying the date in the provided text.

Analyst target and fair value revisions mentioned

A separate update in the provided text said analysts trimmed their price target for Max Healthcare Institute to about ₹1,173 from roughly ₹1,201. It also stated that “Fair Value” was revised from ₹1,201.04 to ₹1,172.62, described as a small downward adjustment to implied valuation. The discount rate used in the valuation was said to have moved from 12.514% to 12.436%. These changes were presented as revisions to model inputs rather than company-issued guidance. No explanation was provided for the revisions beyond the numerical changes.

Other corporate items referenced

The provided text also referenced that the re-appointment of Mr. Anil Kumar Bhatnagar as Director was approved. Separately, it mentioned an NCLT observation of a procedural defect related to an incorrect Postal Ballot Notice, with permission granted to rectify it by filing an additional affidavit. The snippet did not provide further context on the parties involved, the underlying matter, or the timeline for compliance. As presented, these items appeared as additional corporate governance and legal process updates alongside the results and capex decisions. Investors typically track such references for any potential follow-on disclosures.

Key numbers at a glance

Why the update matters

The combination of quarterly financial approval and a large hospital expansion plan makes the board meeting update relevant for both near-term tracking and long-term capacity planning. The ₹425 crore capex and ~250-bed addition at Vaishali indicates continued emphasis on adding physical infrastructure. Management changes across procurement, supply chain, and experience and brand functions signal internal leadership reshaping while the expansion is being pursued. The in-principle approval to evaluate medical colleges and medical institutions highlights how proposed NMC amendments could open new formats for healthcare companies incorporated under the Companies Act, 2013. The next immediate milestone on the communication calendar, based on the provided information, is the investor and analyst earnings call scheduled for August 14, 2026 at 11:00 AM IST.